← PTHS
PTHS— Pelthos Therapeutics Inc.
MaterialsBiological Products, (No Diagnostic Substances)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| General and administrative expenses | $4.1M+50.1% | $2.7M+149.3% | $1.1M |
| Research and development | $1.2M-54.3% | $2.6M+558.5% | $392K |
| Professional fees | $2.3M+47.8% | $1.5M+86.6% | $828K |
| Total operating expenses | $7.6M+10.3% | $6.9M+196.0% | $2.3M |
| NET LOSS FROM OPERATIONS | -$7.6M-10.3% | -$6.9M-196.0% | -$2.3M |
| Interest expense | -$786K-51.7% | -$519K-269.2% | -$140K |
| Other income | $39K | — | — |
| Gain on default judgement | $363K | — | — |
| Total other (expense) income | -$383K+26.1% | -$519K-269.2% | -$140K |
| Net loss before provision for income taxes | -$8.0M-7.8% | -$7.4M-200.2% | -$2.5M |
| NET LOSS | -$8.0M-7.8% | -$7.4M-200.2% | -$2.5M |
| Net loss per common share - diluted | -$1.43+75.3% | -$5.78 | — |
| Weighted average number of common shares outstanding during the year - diluted | $5.6M+336.7% | $1.3M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.